Phaseline

Companies › Oncotelic

Oncotelic: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 1 Phase 2, 1 Phase 3, 1 Phase 1; Oncology, Ophthalmology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Trabedersen (OT-101)
Transforming growth factor beta-2 mRNA antisense inhibitor
TGFB2Phase 2Pancreatic Ductal Adenocarcinoma; Myopia, Progressive; Non-small Cell Lung CancerJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04770610Trabedersen (OT-101)Phase 3Myopia, ProgressiveOphthalmologyMar 2027
NCT06079346Trabedersen (OT-101)Phase 2Pancreatic Ductal AdenocarcinomaOncologyJun 2027
NCT06579196Trabedersen (OT-101)Phase 1Non-small Cell Lung CancerOncologyMar 2028

From the company's SEC filings

Cash of $0m on 2026-06-30; operating cash outflow about $1m a year; runway about 2 months at that burn, to Sep 2026; 0 of 2 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Agreements filed with the SEC (item 1.01), last two years

Targets

TGFB2 (1)

Companies with the same targets

Bristol-Myers Squibb

Companies built like this

Dogwood Therapeutics Atossa Therapeutics Curis Processa Pharmaceuticals Moleculin Biotech

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.